{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T21:34:45Z","timestamp":1792618485218,"version":"4.5.0"},"reference-count":75,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AR069114"],"award-info":[{"award-number":["AR069114"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","theclinics.com","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Dermatologic Clinics"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.det.2016.11.014","type":"journal-article","created":{"date-parts":[[2017,3,16]],"date-time":"2017-03-16T22:21:22Z","timestamp":1489702882000},"page":"257-265","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":183,"title":["Vitiligo Pathogenesis and Emerging Treatments"],"prefix":"10.1016","volume":"35","author":[{"given":"Mehdi","family":"Rashighi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John E.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9988","key":"10.1016\/j.det.2016.11.014_bib1","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S0140-6736(14)60763-7","article-title":"Vitiligo","volume":"386","author":"Ezzedine","year":"2015","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.det.2016.11.014_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nrdp.2015.11","article-title":"Vitiligo","volume":"1","author":"Picardo","year":"2015","journal-title":"Nat Rev Dis Primers"},{"issue":"21","key":"10.1016\/j.det.2016.11.014_bib3","first-page":"343","article-title":"Interfering with the IFN-gamma\/CXCL10 pathway to develop new targeted treatments for vitiligo","volume":"3","author":"Rashighi","year":"2015","journal-title":"Ann Transl Med"},{"issue":"2","key":"10.1016\/j.det.2016.11.014_bib4","first-page":"160","article-title":"Clinical practice. Vitiligo","volume":"360","author":"Taieb","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.det.2016.11.014_bib5","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1034\/j.1600-0749.2003.00032.x","article-title":"Epidemiology of vitiligo and associated autoimmune diseases in Caucasian probands and their families","volume":"16","author":"Alkhateeb","year":"2003","journal-title":"Pigment Cell Res"},{"issue":"2","key":"10.1016\/j.det.2016.11.014_bib6","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.jaad.2015.08.063","article-title":"Comorbid autoimmune diseases in patients with vitiligo: a cross-sectional study","volume":"74","author":"Gill","year":"2016","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.det.2016.11.014_bib7","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/ng.2272","article-title":"Genome-wide association analyses identify 13 new susceptibility loci for generalized vitiligo","volume":"44","author":"Jin","year":"2012","journal-title":"Nat Genet"},{"key":"10.1016\/j.det.2016.11.014_bib8","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3389\/fgene.2016.00003","article-title":"Genetic susceptibility to vitiligo: GWAS approaches for identifying vitiligo susceptibility genes and loci","volume":"7","author":"Shen","year":"2016","journal-title":"Front Genet"},{"issue":"2","key":"10.1016\/j.det.2016.11.014_bib9","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/jid.2011.321","article-title":"Six decades of vitiligo genetics: genome-wide studies provide insights into autoimmune pathogenesis","volume":"132","author":"Spritz","year":"2012","journal-title":"J\u00a0Invest Dermatol"},{"issue":"1","key":"10.1016\/j.det.2016.11.014_bib10","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/imr.12369","article-title":"Cellular stress and innate inflammation in organ-specific autoimmunity: lessons learned from vitiligo","volume":"269","author":"Harris","year":"2016","journal-title":"Immunol Rev"},{"issue":"3","key":"10.1016\/j.det.2016.11.014_bib11","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/1523-1747.ep12480976","article-title":"Structural aberration of the rough endoplasmic reticulum and melanosome compartmentalization in long-term cultures of melanocytes from vitiligo patients","volume":"97","author":"Boissy","year":"1991","journal-title":"J\u00a0Invest Dermatol"},{"issue":"1","key":"10.1016\/j.det.2016.11.014_bib12","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/sj.jidsp.5640189","article-title":"In\u00a0vivo and in\u00a0vitro evidence for hydrogen peroxide (H2O2) accumulation in the epidermis of patients with vitiligo and its successful removal by a UVB-activated pseudocatalase","volume":"4","author":"Schallreuter","year":"1999","journal-title":"J\u00a0Investig Dermatol Symp Proc"},{"issue":"9","key":"10.1016\/j.det.2016.11.014_bib13","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/j.1600-0625.2008.00697.x","article-title":"Presence of epidermal allantoin further supports oxidative stress in vitiligo","volume":"17","author":"Shalbaf","year":"2008","journal-title":"Exp Dermatol"},{"issue":"4","key":"10.1016\/j.det.2016.11.014_bib14","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1111\/j.1365-2230.2004.01524.x","article-title":"Oxidant-antioxidant enzymes and lipid peroxidation in generalized vitiligo","volume":"29","author":"Koca","year":"2004","journal-title":"Clin Exp Dermatol"},{"issue":"5","key":"10.1016\/j.det.2016.11.014_bib15","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1038\/sj.jid.5700700","article-title":"Membrane lipid alterations as a possible basis for melanocyte degeneration in vitiligo","volume":"127","author":"Dell'Anna","year":"2007","journal-title":"J\u00a0Invest Dermatol"},{"issue":"6","key":"10.1016\/j.det.2016.11.014_bib16","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1111\/1523-1747.ep12492612","article-title":"Low catalase levels in the epidermis of patients with vitiligo","volume":"97","author":"Schallreuter","year":"1991","journal-title":"J\u00a0Invest Dermatol"},{"issue":"12","key":"10.1016\/j.det.2016.11.014_bib17","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1038\/sj.jid.5700612","article-title":"Computer simulation of native epidermal enzyme structures in the presence and absence of hydrogen peroxide (H2O2): potential and pitfalls","volume":"126","author":"Gibbons","year":"2006","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.det.2016.11.014_bib18","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1001\/jama.1939.72800350003010a","article-title":"Occupational leukoderma preliminary report","volume":"113","author":"Oliver","year":"1939","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.det.2016.11.014_bib19","first-page":"278","article-title":"Differential diagnosis of idiopathic vitiligo. Part III: occupational leukoderma","volume":"53","author":"Fisher","year":"1994","journal-title":"Cutis"},{"issue":"6","key":"10.1016\/j.det.2016.11.014_bib20","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1111\/pcmr.12402","article-title":"Use of permanent hair dyes and risk of vitiligo in women","volume":"28","author":"Wu","year":"2015","journal-title":"Pigment Cell Melanoma Res"},{"issue":"5","key":"10.1016\/j.det.2016.11.014_bib21","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/pcmr.12393","article-title":"Melanins and melanogenesis: from pigment cells to human health and technological applications","volume":"28","author":"d'Ischia","year":"2015","journal-title":"Pigment Cell Melanoma Res"},{"issue":"11","key":"10.1016\/j.det.2016.11.014_bib22","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1038\/jid.2012.181","article-title":"Vitiligo-inducing phenols activate the unfolded protein response in melanocytes resulting in upregulation of IL6 and IL8","volume":"132","author":"Toosi","year":"2012","journal-title":"J\u00a0Invest Dermatol"},{"issue":"6","key":"10.1016\/j.det.2016.11.014_bib23","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1038\/jid.2011.16","article-title":"Skin-depigmenting agent monobenzone induces potent T-cell autoimmunity toward pigmented cells by tyrosinase haptenation and melanosome autophagy","volume":"131","author":"van den Boorn","year":"2011","journal-title":"J\u00a0Invest Dermatol"},{"issue":"4","key":"10.1016\/j.det.2016.11.014_bib24","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1111\/j.0022-202X.2005.23653.x","article-title":"4-Tertiary butyl phenol exposure sensitizes human melanocytes to dendritic cell-mediated killing: relevance to vitiligo","volume":"124","author":"Kroll","year":"2005","journal-title":"J\u00a0Invest Dermatol"},{"issue":"174","key":"10.1016\/j.det.2016.11.014_bib25","doi-asserted-by":"crossref","first-page":"174ra28","DOI":"10.1126\/scitranslmed.3005127","article-title":"Mutant HSP70 reverses autoimmune depigmentation in vitiligo","volume":"5","author":"Mosenson","year":"2013","journal-title":"Sci Transl Med"},{"issue":"8","key":"10.1016\/j.det.2016.11.014_bib26","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1073\/pnas.1222808110","article-title":"NLRP1 haplotypes associated with vitiligo and autoimmunity increase interleukin-1beta processing via the NLRP1 inflammasome","volume":"110","author":"Levandowski","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"10.1016\/j.det.2016.11.014_bib27","doi-asserted-by":"crossref","first-page":"e51040","DOI":"10.1371\/journal.pone.0051040","article-title":"Transcriptome analysis reveals markers of aberrantly activated innate immunity in vitiligo lesional and non-lesional skin","volume":"7","author":"Yu","year":"2012","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.det.2016.11.014_bib28","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1016\/j.immuni.2016.05.008","article-title":"Inflammasome-dependent induction of adaptive NK cell memory","volume":"44","author":"van den Boorn","year":"2016","journal-title":"Immunity"},{"issue":"6","key":"10.1016\/j.det.2016.11.014_bib29","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.coi.2013.10.010","article-title":"Innate immune mechanisms in vitiligo: danger from within","volume":"25","author":"Richmond","year":"2013","journal-title":"Curr Opin Immunol"},{"issue":"6","key":"10.1016\/j.det.2016.11.014_bib30","doi-asserted-by":"crossref","first-page":"4299","DOI":"10.4049\/jimmunol.180.6.4299","article-title":"Hsp70 translocates into the plasma membrane after stress and is released into the extracellular environment in a membrane-associated form that activates macrophages","volume":"180","author":"Vega","year":"2008","journal-title":"J\u00a0Immunol"},{"issue":"9","key":"10.1016\/j.det.2016.11.014_bib31","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1111\/exd.12183","article-title":"A\u00a0central role for inducible heat-shock protein 70 in autoimmune vitiligo","volume":"22","author":"Mosenson","year":"2013","journal-title":"Exp Dermatol"},{"issue":"9","key":"10.1016\/j.det.2016.11.014_bib32","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1038\/jid.2009.32","article-title":"Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients","volume":"129","author":"van den Boorn","year":"2009","journal-title":"J\u00a0Invest Dermatol"},{"issue":"4","key":"10.1016\/j.det.2016.11.014_bib33","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/MOP.0000000000000375","article-title":"Understanding autoimmunity of vitiligo and alopecia areata","volume":"28","author":"Rork","year":"2016","journal-title":"Curr Opin Pediatr"},{"issue":"223","key":"10.1016\/j.det.2016.11.014_bib34","doi-asserted-by":"crossref","first-page":"223ra23","DOI":"10.1126\/scitranslmed.3007811","article-title":"CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo","volume":"6","author":"Rashighi","year":"2014","journal-title":"Sci translational Med"},{"issue":"12","key":"10.1016\/j.det.2016.11.014_bib35","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1038\/jid.2015.335","article-title":"Transcriptional analysis of vitiligo skin reveals the alteration of WNT pathway: a promising target for repigmenting vitiligo patients","volume":"135","author":"Regazzetti","year":"2015","journal-title":"J\u00a0Invest Dermatol"},{"issue":"6","key":"10.1016\/j.det.2016.11.014_bib36","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1111\/bjd.14416","article-title":"Increased expression of CXCR3 and its ligands in vitiligo patients and CXCL10 as a potential clinical marker for vitiligo","volume":"174","author":"Wang","year":"2016","journal-title":"Br J Dermatol"},{"issue":"7","key":"10.1016\/j.det.2016.11.014_bib37","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1038\/jid.2011.463","article-title":"A\u00a0mouse model of vitiligo with focused epidermal depigmentation requires IFN-gamma for autoreactive CD8(+) T-cell accumulation in the skin","volume":"132","author":"Harris","year":"2012","journal-title":"J\u00a0Invest Dermatol"},{"issue":"3","key":"10.1016\/j.det.2016.11.014_bib38","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1159\/000246690","article-title":"Treatment of vitiligo with a topical application of pseudocatalase and calcium in combination with short-term UVB exposure: a case study on 33 patients","volume":"190","author":"Schallreuter","year":"1995","journal-title":"Dermatology"},{"issue":"8","key":"10.1016\/j.det.2016.11.014_bib39","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1046\/j.1365-4362.2002.01463.x","article-title":"Rapid initiation of repigmentation in vitiligo with Dead Sea climatotherapy in combination with pseudocatalase (PC-KUS)","volume":"41","author":"Schallreuter","year":"2002","journal-title":"Int J Dermatol"},{"issue":"7","key":"10.1016\/j.det.2016.11.014_bib40","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/j.1365-4632.2008.03660.x","article-title":"From basic research to the bedside: efficacy of topical treatment with pseudocatalase PC-KUS in 71 children with vitiligo","volume":"47","author":"Schallreuter","year":"2008","journal-title":"Int J Dermatol"},{"issue":"8","key":"10.1016\/j.det.2016.11.014_bib41","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1046\/j.1365-2230.2002.01142.x","article-title":"Topical pseudocatalase mousse and narrowband UVB phototherapy is not effective for vitiligo: an open, single-centre study","volume":"27","author":"Patel","year":"2002","journal-title":"Clin Exp Dermatol"},{"issue":"4","key":"10.1016\/j.det.2016.11.014_bib42","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1111\/j.1365-2133.2009.09252.x","article-title":"A\u00a0randomized, double-blinded, placebo-controlled trial of pseudocatalase cream and narrowband ultraviolet B in the treatment of vitiligo","volume":"161","author":"Bakis-Petsoglou","year":"2009","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.det.2016.11.014_bib43","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/j.1365-2133.2009.09292.x","article-title":"Pseudocatalase and narrowband ultraviolet B for vitiligo: clearing the picture","volume":"161","author":"Gawkrodger","year":"2009","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.det.2016.11.014_bib44","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s40257-015-0153-5","article-title":"Alternative systemic treatments for vitiligo: a review","volume":"16","author":"Cohen","year":"2015","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.det.2016.11.014_bib45","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1472-6882-11-21","article-title":"Ginkgo biloba for the treatment of vitilgo vulgaris: an open label pilot clinical trial","volume":"11","author":"Szczurko","year":"2011","journal-title":"BMC Complement Altern Med"},{"issue":"3","key":"10.1016\/j.det.2016.11.014_bib46","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1046\/j.1365-2230.2003.01207.x","article-title":"Effectiveness of oral Ginkgo biloba in treating limited, slowly spreading vitiligo","volume":"28","author":"Parsad","year":"2003","journal-title":"Clin Exp Dermatol"},{"issue":"7","key":"10.1016\/j.det.2016.11.014_bib47","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1111\/j.1468-3083.2006.02132.x","article-title":"Treatment of vitiligo vulgaris with narrow-band UVB and oral Polypodium leucotomos extract: a randomized double-blind placebo-controlled study","volume":"21","author":"Middelkamp-Hup","year":"2007","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"6","key":"10.1016\/j.det.2016.11.014_bib48","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/j.1365-2230.2007.02514.x","article-title":"Antioxidants and narrow band-UVB in the treatment of vitiligo: a double-blind placebo controlled trial","volume":"32","author":"Dell'Anna","year":"2007","journal-title":"Clin Exp Dermatol"},{"issue":"1","key":"10.1016\/j.det.2016.11.014_bib49","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/j.1755-148X.2011.00916.x","article-title":"HSP70i is a critical component of the immune response leading to vitiligo","volume":"25","author":"Mosenson","year":"2012","journal-title":"Pigment Cell Melanoma Res"},{"issue":"1","key":"10.1016\/j.det.2016.11.014_bib50","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4049\/jimmunol.1401867","article-title":"Mechanisms of Jak\/STAT signaling in immunity and disease","volume":"194","author":"Villarino","year":"2015","journal-title":"J\u00a0Immunol"},{"issue":"10","key":"10.1016\/j.det.2016.11.014_bib51","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1001\/jamadermatol.2015.1520","article-title":"Tofacitinib citrate for the treatment of vitiligo: a pathogenesis-directed therapy","volume":"151","author":"Craiglow","year":"2015","journal-title":"JAMA Dermatol"},{"issue":"2","key":"10.1016\/j.det.2016.11.014_bib52","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/nrd3652","article-title":"Ruxolitinib","volume":"11","author":"Mesa","year":"2012","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"10.1016\/j.det.2016.11.014_bib53","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJMoa1409002","article-title":"Ruxolitinib versus standard therapy for the treatment of polycythemia vera","volume":"372","author":"Vannucchi","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.det.2016.11.014_bib54","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jaad.2015.09.073","article-title":"Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA)","volume":"74","author":"Harris","year":"2016","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"7","key":"10.1016\/j.det.2016.11.014_bib55","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1517\/14740338.2014.916273","article-title":"Safety evaluation of ruxolitinib for treating myelofibrosis","volume":"13","author":"Galli","year":"2014","journal-title":"Expert Opin Drug Saf"},{"issue":"4","key":"10.1016\/j.det.2016.11.014_bib56","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1001\/jamadermatol.2015.4445","article-title":"Topical ruxolitinib for the treatment of alopecia universalis","volume":"152","author":"Craiglow","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.det.2016.11.014_bib57","series-title":"Topical ruxolitinib for the treatment of vitiligo","author":"Tufts Medical Center","year":"2000"},{"issue":"5","key":"10.1016\/j.det.2016.11.014_bib58","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1038\/jid.2011.41","article-title":"Statins downregulate K6a promoter activity: a possible therapeutic avenue for pachyonychia congenita","volume":"131","author":"Zhao","year":"2011","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.det.2016.11.014_bib59","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1476-511X-3-7","article-title":"Positive pleiotropic effects of HMG-CoA reductase inhibitor on vitiligo","volume":"3","author":"Noel","year":"2004","journal-title":"Lipids Health Dis"},{"issue":"4","key":"10.1016\/j.det.2016.11.014_bib60","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1038\/jid.2014.529","article-title":"Simvastatin prevents and reverses depigmentation in a mouse model of vitiligo","volume":"135","author":"Agarwal","year":"2015","journal-title":"J\u00a0Invest Dermatol"},{"issue":"1","key":"10.1016\/j.det.2016.11.014_bib61","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.jaad.2016.06.015","article-title":"A small doubleblind, placebo-controlled, phase-II, proof-of-concept clinical trial to evaluate oral simvastatin as a treatment for vitiligo","volume":"76","author":"Vanderweil","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.det.2016.11.014_bib62","series-title":"Atorvastatin in active vitiligo","author":"Centre Hospitalier Universitaire de Nice","year":"2000"},{"issue":"5","key":"10.1016\/j.det.2016.11.014_bib63","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1053\/j.seminoncol.2010.09.005","article-title":"Immune checkpoint proteins: a new therapeutic paradigm for cancer\u2013preclinical background: CTLA-4 and PD-1 blockade","volume":"37","author":"Weber","year":"2010","journal-title":"Semin Oncol"},{"issue":"2","key":"10.1016\/j.det.2016.11.014_bib64","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.jaad.2014.07.033","article-title":"Cutaneous adverse effects of targeted therapies: part II: inhibitors of intracellular molecular signaling pathways","volume":"72","author":"Macdonald","year":"2015","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2016.11.014_bib65","article-title":"Targeting CTLA-4, PD-L1 and IDO to modulate immune responses in vitiligo","author":"Speeckaert","year":"2016","journal-title":"Exp Dermatol"},{"issue":"3","key":"10.1016\/j.det.2016.11.014_bib66","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/nrd1989","article-title":"Abatacept","volume":"5","author":"Moreland","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.det.2016.11.014_bib67","series-title":"Open-label pilot study of abatacept for the treatment of vitiligo","author":"Brigham and Women's Hospital","year":"2000"},{"key":"10.1016\/j.det.2016.11.014_bib68","unstructured":"Genexin.com [Internet]. Available at: http:\/\/www.genexine.com\/m31.php. Accessed June 30, 2016."},{"issue":"Suppl\u00a02","key":"10.1016\/j.det.2016.11.014_bib69","first-page":"147","article-title":"The mechanisms of action of phototherapy in the treatment of the most common dermatoses","volume":"35","author":"Bulat","year":"2011","journal-title":"Coll Antropol"},{"issue":"1","key":"10.1016\/j.det.2016.11.014_bib70","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1590\/S0365-05962013000100009","article-title":"Mechanisms regulating melanogenesis","volume":"88","author":"Videira","year":"2013","journal-title":"An Bras Dermatol"},{"issue":"7","key":"10.1016\/j.det.2016.11.014_bib71","first-page":"775","article-title":"A\u00a0review and update on melanocyte stimulating hormone therapy: afamelanotide","volume":"12","author":"Fabrikant","year":"2013","journal-title":"J\u00a0Drugs Dermatol"},{"issue":"1","key":"10.1016\/j.det.2016.11.014_bib72","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1001\/2013.jamadermatol.386","article-title":"The efficacy of afamelanotide and narrowband UV-B phototherapy for repigmentation of vitiligo","volume":"149","author":"Grimes","year":"2013","journal-title":"JAMA Dermatol"},{"issue":"1","key":"10.1016\/j.det.2016.11.014_bib73","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1001\/jamadermatol.2014.1875","article-title":"Afamelanotide and narrowband UV-B phototherapy for the treatment of vitiligo: a randomized multicenter trial","volume":"151","author":"Lim","year":"2015","journal-title":"JAMA Dermatol"},{"issue":"12","key":"10.1016\/j.det.2016.11.014_bib74","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1038\/jid.2015.372","article-title":"Melanocyte regeneration in vitiligo requires WNT beneath their Wings","volume":"135","author":"Harris","year":"2015","journal-title":"J\u00a0Invest Dermatol"},{"issue":"4","key":"10.1016\/j.det.2016.11.014_bib75","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/dth.12115","article-title":"Novel topical cream delivers safe and effective sunlight therapy for vitiligo by selectively filtering damaging ultraviolet radiation","volume":"27","author":"Goren","year":"2014","journal-title":"Dermatol Ther"}],"container-title":["Dermatologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863516301413?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863516301413?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,12,4]],"date-time":"2021-12-04T12:14:05Z","timestamp":1638620045000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733863516301413"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":75,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["S0733863516301413"],"URL":"https:\/\/doi.org\/10.1016\/j.det.2016.11.014","relation":{},"ISSN":["0733-8635"],"issn-type":[{"value":"0733-8635","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vitiligo Pathogenesis and Emerging Treatments","name":"articletitle","label":"Article Title"},{"value":"Dermatologic Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.det.2016.11.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}